| __timestamp | Agios Pharmaceuticals, Inc. | AstraZeneca PLC |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 13324000000 |
| Thursday, January 1, 2015 | 35992000 | 11451000000 |
| Friday, January 1, 2016 | 50714000 | 9739000000 |
| Sunday, January 1, 2017 | 71124000 | 10543000000 |
| Monday, January 1, 2018 | 114145000 | 10362000000 |
| Tuesday, January 1, 2019 | 132034000 | 11848000000 |
| Wednesday, January 1, 2020 | 149070000 | 11693000000 |
| Friday, January 1, 2021 | 121445000 | 15680000000 |
| Saturday, January 1, 2022 | 121673000 | 18955000000 |
| Sunday, January 1, 2023 | 119903000 | 18025000000 |
| Monday, January 1, 2024 | 156784000 | 20532000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of two prominent companies: AstraZeneca PLC and Agios Pharmaceuticals, Inc., from 2014 to 2023.
AstraZeneca, a global leader, consistently outpaces Agios in SG&A spending, reflecting its expansive operations. In 2022, AstraZeneca's SG&A expenses peaked at approximately $18.96 billion, a 95% increase from 2016. Meanwhile, Agios, a smaller biotech firm, saw its SG&A expenses grow by 139% over the same period, reaching around $121.67 million in 2022.
These trends highlight AstraZeneca's robust market presence and Agios's strategic growth. Investors and industry analysts can glean insights into each company's operational strategies and market positioning through these financial metrics.
Breaking Down SG&A Expenses: Eli Lilly and Company vs Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and AstraZeneca PLC
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and United Therapeutics Corporation
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Insmed Incorporated
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Wave Life Sciences Ltd.
Selling, General, and Administrative Costs: Agios Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.